Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of CKD-386 vs Co-administration of D012, D326, D337 in Healthy Volunteers
NCT04223895Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Feb 2020
- Primary completion
- Mar 2020
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of ezetimibe + rosuvastatin + telmisartan in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area under the concentration-time curve from time zero to time t and Maximum Plasma Concentration. Status: unknown.
02
Drugs
ezetimibe + rosuvastatin + telmisartan
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04223895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04223895.